Open-Angle Glaucoma

Ophthalmology
60
Pipeline Programs
8
Companies
50
Clinical Trials
1 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
3
12
1
22
21
Early DiscoveryClinical DevelopmentMarket

On Market (4)

Approved therapies currently available

U
BIMATOPROSTApproved
bimatoprost
Unknown Company
Prostaglandin Analog [EPC]ophthalmic2022
AbbVie
DURYSTAApproved
bimatoprost
AbbVie
Prostaglandin Analog [EPC]ophthalmic2020
AbbVie
LATISSEApproved
bimatoprost
AbbVie
Prostaglandin Analog [EPC]topical2008
AbbVie
LUMIGANApproved
bimatoprost
AbbVie
ophthalmic2001

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Alcon
AlconFORT WORTH, TX
35 programs
8
1
14
11
Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspensionPhase 4
Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspensionPhase 41 trial
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspensionPhase 41 trial
DuoTravPhase 41 trial
DuoTravPhase 41 trial
+30 more programs
Active Trials
NCT01485822TerminatedEst. Feb 2012
NCT00069706CompletedEst. Oct 2003
NCT00372931Completed
+31 more trials
Glaukos
GlaukosALISO VIEJO, CA
8 programs
5
Implantation of two iStent inject micro-bypass stentsPhase 41 trial
StentPhase 41 trial
iStentPhase 41 trial
iStentPhase 41 trial
iStent injectPhase 41 trial
+3 more programs
Active Trials
NCT01455467CompletedEst. Oct 2019
NCT01444105CompletedEst. Apr 2019
NCT01456390CompletedEst. Mar 2019
+5 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
6 programs
1
4
1
BimatoprostPhase 31 trial
Bimatoprost SRPhase 31 trial
Bimatoprost SRPhase 31 trial
XEN45Phase 32 trials
AGN-193408 SRPhase 1/21 trial
+1 more programs
Active Trials
NCT05338606No Longer Available
NCT04499248Recruiting96Est. Feb 2029
NCT03850782Completed515Est. Aug 2025
+4 more trials
Novartis
NovartisBASEL, Switzerland
1 program
1
Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspensionPhase 41 trial
Active Trials
NCT02325518Completed218Est. Dec 2015
S
SantenCA - Emeryville
7 programs
2
4
1
Tafluprost 0.0015%Phase 31 trial
DE-104 ophthalmic solutionPhase 21 trial
DE-104 ophthalmic solution, low concentrationPhase 21 trial
DE-104 ophthalmic solution, low concentrationPhase 21 trial
DE-117 Low Dose ophthalmic solutionPhase 21 trial
+2 more programs
Active Trials
NCT00868894Completed49Est. Jun 2010
NCT01279083Completed147Est. Feb 2012
NCT00656240Completed
+4 more trials
Bausch + Lomb
Bausch + LombNJ - Bridgewater
2 programs
2
BOL-303259-XPhase 31 trial
BOL-303259-XPhase 31 trial
Active Trials
NCT01749930Completed420Est. May 2015
NCT01749904Completed420Est. Sep 2015
M&
Merck & Co.RAHWAY, NJ
1 program
1
Preservative-Free TafluprostPhase 31 trial
Active Trials
NCT01026831Completed643Est. Sep 2010
Annexon Biosciences
Annexon BiosciencesCA - Brisbane
1 program
1
ANX007Phase 11 trial
Active Trials
NCT03488550CompletedEst. Aug 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
AbbVieXEN45
AlconBrinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
AlconBrinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension
NovartisBrinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension
GlaukosImplantation of two iStent inject micro-bypass stents
AlconTravoprost/timolol fixed combination
GlaukosiStent inject
GlaukosiStent
AlconDuoTrav
AlconDuoTrav
AlconTravoprost ophthalmic solution 0.004% with SofZia® preservative system
AlconTravoprost 0.004% / Timolol maleate 0.5%
AlconTravoprost 0.004%/timolol 0.5% fixed combination eye drops
AlconTravoprost ophthalmic solution 0.004% with SofZia® preservative system
GlaukosStent

Showing 15 of 48 trials with date data

Clinical Trials (50)

Total enrollment: 8,030 patients across 50 trials

NCT05821855AbbVieXEN45

A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China

Start: Dec 2023Est. completion: Jul 2030130 patients
Phase 4Recruiting
NCT02730871AlconBrinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

Start: Jun 2016Est. completion: Jul 2018
Phase 4Terminated
NCT02419508AlconBrinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

Start: Aug 2015Est. completion: Feb 2018290 patients
Phase 4Completed
NCT02325518NovartisBrinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension

Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution

Start: Dec 2014Est. completion: Dec 2015218 patients
Phase 4Completed
NCT02873806GlaukosImplantation of two iStent inject micro-bypass stents

Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents

Start: Mar 2013Est. completion: Nov 2019
Phase 4Completed
NCT01510132AlconTravoprost/timolol fixed combination

Travacom Post Marketing Surveillance Study

Start: Jan 2012Est. completion: Jan 20120
Phase 4Withdrawn
NCT01444040GlaukosiStent inject

Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost

Start: Sep 2011Est. completion: Mar 2019
Phase 4Completed
NCT01443988GlaukosiStent

Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost

Start: Sep 2011Est. completion: Apr 2017
Phase 4Completed
NCT00828906AlconDuoTrav

DuoTrav® Eye Drops As Replacement Therapy Program

Start: Feb 2009
Phase 4Completed
NCT00887029AlconDuoTrav

A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma

Start: Jan 2009Est. completion: Nov 2009
Phase 4Completed
NCT00798759AlconTravoprost ophthalmic solution 0.004% with SofZia® preservative system

Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN

Start: Dec 2008Est. completion: May 2009236 patients
Phase 4Completed
NCT00759239AlconTravoprost 0.004% / Timolol maleate 0.5%

Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Start: Sep 2008Est. completion: Jan 2011
Phase 4Completed
NCT00508469AlconTravoprost 0.004%/timolol 0.5% fixed combination eye drops

Adherence Assessment With Travalert Dosing Aid

Start: Oct 2007Est. completion: Jan 2010
Phase 4Completed
NCT00527592AlconTravoprost ophthalmic solution 0.004% with SofZia® preservative system

A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Start: May 2007Est. completion: Aug 200854 patients
Phase 4Completed
NCT00326079GlaukosStent

A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2

Start: Aug 2004Est. completion: May 2013
Phase 4Unknown
NCT00326014GlaukosiStent

A Study of the Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects.

Start: Apr 2003Est. completion: Dec 2009
Phase 4Completed
NCT00047606AlconIOP Lowering Medications

Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32

Start: Aug 2002Est. completion: Nov 2003
Phase 4Terminated
NCT05411198AbbVieXEN45

Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

Start: Jul 2022Est. completion: Feb 202674 patients
Phase 3Completed
NCT04285580AbbVieBimatoprost SR

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Start: Jun 2020Est. completion: May 202237 patients
Phase 3Completed
NCT03891446AbbVieBimatoprost SR

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

Start: Mar 2019Est. completion: Aug 2026455 patients
Phase 3Active Not Recruiting
NCT03850782AbbVieBimatoprost

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Start: Feb 2019Est. completion: Aug 2025515 patients
Phase 3Completed
NCT01749904Bausch + LombBOL-303259-X

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Start: Jan 2013Est. completion: Sep 2015420 patients
Phase 3Completed
NCT01749930Bausch + LombBOL-303259-X

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Start: Jan 2013Est. completion: May 2015420 patients
Phase 3Completed
NCT01453855AlconTravoprost ophthalmic solution, 0.003%

Travoprost 3-Month Safety and Efficacy Study

Start: Nov 2011Est. completion: Aug 2012
Phase 3Completed
NCT01309204AlconBrinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Start: May 2011Est. completion: Jan 20131,184 patients
Phase 3Completed
NCT01310777AlconBrinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Start: May 2011Est. completion: Jan 2013
Phase 3Completed
NCT01297517AlconBrinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension

Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%

Start: Feb 2011Est. completion: Mar 20121,001 patients
Phase 3Completed
NCT01026831Merck & Co.Preservative-Free Tafluprost

Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)

Start: Jan 2010Est. completion: Sep 2010643 patients
Phase 3Completed
NCT00928590AlconTravoprost/Timolol Maleate Fixed Combination solution

Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular Hypertension

Start: Jul 2009Est. completion: Nov 2010
Phase 3Completed
NCT00862472AlconDuoTrav APS

Safety and Efficacy Study of DuoTrav APS Versus DuoTrav

Start: Mar 2009Est. completion: Jun 20090
Phase 3Withdrawn
NCT00761319AlconTravoprost ophthalmic solution 0.004% with SofZia® preservative system

Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health

Start: Oct 2008Est. completion: Sep 2009705 patients
Phase 3Completed
NCT00690794AlconTravoprost ophthalmic solution 0.004% with SofZia® preservative system

Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension

Start: Jul 2008Est. completion: May 2009726 patients
Phase 3Completed
NCT00465803AlconTravoprost 0.004%/timolol 0.5% ophthalmic solution

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

Start: Mar 2007
Phase 3Completed
NCT00314158AlconBrinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Start: Nov 2005Est. completion: Jan 2007
Phase 3Completed
NCT00918346SantenTafluprost 0.0015%

Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation

Start: Sep 2005Est. completion: Apr 200643 patients
Phase 3Completed
NCT00293787AlconTravoprost 0.004% / Timolol 0.5% Ophthalmic Solution

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Start: Jun 2004Est. completion: Aug 2005
Phase 3Completed
NCT00047515AlconAlcon Investigational Agent

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69

Start: Jan 2001Est. completion: Dec 2003
Phase 3Completed
NCT00047528AlconAlcon Investigational Agent

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41

Start: Jan 2001Est. completion: Nov 2003
Phase 3Completed
NCT00047593AlconIOP Lowering Medications

Phase 3 Study Comparing IOP Lowering in OAG or OH in Japanese Subjects C-01-98

Start: Jan 2000Est. completion: Jul 2004
Phase 3Completed
NCT00705770AlconAnecortave Acetate

A Multi-Dose Study With a Treatment for Open-Angle Glaucoma

Start: May 2008Est. completion: Jul 2008
Phase 2/3Withdrawn
NCT00657579SantenDE-104 ophthalmic solution, low concentration

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 2Completed
NCT00656240SantenDE-104 ophthalmic solution

To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 2Completed
NCT02179008SantenDE-117 Low Dose ophthalmic solution

Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Start: Jun 2014Est. completion: Jan 2015184 patients
Phase 2Completed
NCT01298687AlconTravoprost Ophthalmic Solution, 0.00013%

Divided Dose of TRAVATAN®

Start: Feb 2011Est. completion: Apr 2011
Phase 2Completed
NCT00961649AlconBrinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension

Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination

Start: Oct 2009Est. completion: Feb 2010195 patients
Phase 2Terminated
NCT00761709AlconAL-39256 Ophthalmic Suspension, 1%

Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension

Start: Jul 2009Est. completion: Oct 2009
Phase 2Completed
NCT00788541AlconAnecortave Acetate Sterile Suspension, 6 mg/mL

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

Start: Dec 2008Est. completion: Sep 2009197 patients
Phase 2Terminated
NCT00650338SantenDE-104 ophthalmic solution, low concentration

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Start: Mar 2008Est. completion: Oct 2008165 patients
Phase 2Completed
NCT00637130AlconTravoprost ophthalmic solution, 0.0008%

Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost

Start: Oct 2007138 patients
Phase 2Completed
NCT00372931AlconAL-37807

A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension

Start: May 2006
Phase 2Completed

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
4h ago

Cleanroom and Laboratory Technician

SAB BIO
4h ago

Product Specialist

Johnson & Johnson
Hangzhou, Zhejiang, China
20h ago

BM 喀什 PSR HY

Johnson & Johnson
Urumqi, Xinjiang, China
20h ago

Site Delivery Leader MLL

Johnson & Johnson
Gent, East Flanders, Belgium
20h ago

Clinical Operations Manager

Johnson & Johnson
Irvine, California, United States of America
20h ago
$117K - $201K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

22 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 8,030 patients
8 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Glaucoma(92)Dry Eye(74)Age-Related Macular Degeneration(73)Dry Eye Disease(43)Neovascular Age-related Macular Degeneration(40)Macular Degeneration(37)Diabetic Retinopathy(25)Cataracts(22)